

CITATION REPORT

List of articles citing

Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy

DOI: 10.1002/hep.22841
Hepatology, 2009, 49, 1503-14.

Source: <https://exaly.com/paper-pdf/46061099/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
658	Chronic hepatitis B and C: update on therapy. 2009 , 4, 437-452		2
657	HBV and HCV therapy. 2009 , 1, 484-509		6
656	Ultrasensitive genotypic detection of antiviral resistance in hepatitis B virus clinical isolates. 2009 , 53, 2762-72		11
655	Early hepatitis B virological rebound on entecavir through selection of lamivudine-associated mutations. <i>Journal of Antimicrobial Chemotherapy</i> , 2009 , 64, 875-7	5.1	3
654	The saga of entecavir. <i>Hepatology International</i> , 2009 , 3, 421-4	8.8	2
653	On-treatment monitoring of HBV DNA levels: predicting response and resistance to oral antiviral therapy at week 24 versus week 48. <i>Hepatology International</i> , 2009 , 3 Suppl 1, 16-23	8.8	7
652	Current treatment for chronic hepatitis B in Japan. 2009 , 2, 325-330		3
651	Treatment with nucleos(t)ide analogues in chronic hepatitis B: where does the road map lead us?. 2009 , 51, 1-3		8
650	Hepatitis B virus resistance to nucleos(t)ide analogues. 2009 , 137, 1593-608.e1-2		555
649	Entecavir: a review of its use in chronic hepatitis B. 2009 , 69, 1003-33		29
648	Hepatitis: Monitoring drug therapy for hepatitis B--a global challenge?. 2009 , 6, 565-7		11
647	Entecavir for the long-term treatment of chronic hepatitis B. 2009 , 7, 1053-62		9
646	Monotherapy versus combination therapy for the treatment of chronic hepatitis B. 2009 , 18, 1655-66		32
645	Current challenges in viral hepatitis, antimicrobial resistance and the influenza pandemic. 2009 , 7, 945-9		
644	Evolution of hepatitis B virus mutation during entecavir rescue therapy in patients with antiviral resistance to lamivudine and adefovir. 2009 , 14, 985-93		21
643	The Forefront of Treatment of Type B/C Chronic Hepatitis.. 2010 , 99, 3080-3086		
642	Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B. 2010 , 15, 235-41		59

641	New approaches to optimize treatment responses in chronic hepatitis B. 2010 , 15 Suppl 3, 61-8		7
640	Effect of newer oral antiviral agents on future therapy of chronic hepatitis B. 2010 , 15, 13-22		5
639	A personalized approach to optimize hepatitis B treatment in treatment-naive patients. 2010 , 15 Suppl 3, 53-9		8
638	JSH Consensus Kobe 2009: Diagnosis and Treatment of Hepatitis B. 2010 , 51, 243-260		
637	[4. Austrian consensus-statement for diagnosis and therapy of hepatitis B 2009]. 2010 , 122, 280-302		2
636	Efficacy and resistance of entecavir following 3 years of treatment of Japanese patients with lamivudine-refractory chronic hepatitis B. <i>Hepatology International</i> , 2010 , 4, 414-22	8.8	19
635	Evaluation of long-term entecavir treatment in stable chronic hepatitis B patients switched from lamivudine therapy. <i>Hepatology International</i> , 2010 , 4, 594-600	8.8	12
634	A Systematic Review of Side Effects of Nucleoside and Nucleotide Drugs Used for Treatment of Chronic Hepatitis B. 2010 , 9, 75-90		26
633	Antiviral Therapy: Analysis of Long-term Efficacy and Safety. 2010 , 9, 214-222		
632	HBV Drug Resistance Development, Testing, and Prevention. 2010 , 9, 223-230		1
631	[Treatment has a positive impact on the long-term evolution of chronic hepatitis B]. 2010 , 34 Suppl 2, S99-102		1
630	Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. <i>Hepatology</i> , 2010 , 51, 422-30	11.2	433
629	Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. <i>Hepatology</i> , 2010 , 51, 1945-53	11.2	85
628	Drug therapy: tenofovir. <i>Hepatology</i> , 2010 , 52, 743-7	11.2	16
627	Rheumatologists' awareness of and screening practices for hepatitis B virus infection prior to initiating immunomodulatory therapy. 2010 , 62, 704-11		38
626	Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B. 2010 , 82, 1835-42		45
625	Virological, serological and biochemical outcomes through 3 years of entecavir treatment in nucleoside-naive Chinese chronic hepatitis B patients. 2010 , 17 Suppl 1, 51-8		18
624	Endpoints of hepatitis B treatment. 2010 , 17, 675-84		16

623	Efficacy of switching to entecavir monotherapy in Japanese lamivudine-pretreated patients. 2010 , 25, 892-8	13
622	Hepatitis B virus-related membranous nephropathy treated with entecavir. 2010 , 15, 266	7
621	Mechanistic characterization and molecular modeling of hepatitis B virus polymerase resistance to entecavir. 2010 , 5, e9195	29
620	Mechanism of entecavir resistance of hepatitis B virus with viral breakthrough as determined by long-term clinical assessment and molecular docking simulation. 2010 , 54, 882-9	29
619	Differential impact of immune escape mutations G145R and P120T on the replication of lamivudine-resistant hepatitis B virus e antigen-positive and -negative strains. 2010 , 84, 1026-33	32
618	Identification and characterization of clevidine-resistant mutants of hepatitis B virus isolated from chronic hepatitis B patients. 2010 , 84, 4494-503	39
617	Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C. 2010 , 2, 2696-739	31
616	Antiviral treatment of chronic hepatitis B virus (HBV) infections. 2010 , 2, 1279-305	40
615	Is there Emergence of Clinical HBV Resistance Under Long-Term HBV Combination Therapy? A Challenging Case Report. 2010 , 2, 1564-70	2
614	Drug resistance in antiviral therapy. 2010 , 14, 439-59	22
613	Management of end-stage liver disease in chronic hepatitis B. 2010 , 14, 477-93	3
612	New pharmacologic therapies in chronic hepatitis B. 2010 , 39, 659-80	1
611	Antiviral drug resistance: mechanisms and clinical implications. 2010 , 24, 809-33	48
610	Discovery and development of anti-HBV agents and their resistance. 2010 , 15, 5878-908	43
609	Molecular methods in the diagnosis and management of chronic hepatitis B. 2010 , 10, 921-35	12
608	Hepatitis B virus DNA and hepatitis B surface antigen levels in chronic hepatitis B. 2010 , 8, 717-26	15
607	Screening and early treatment of migrants for chronic hepatitis B virus infection is cost-effective. 2010 , 138, 522-30	91
606	Review of hepatitis B therapeutics. 2010 , 51, 1201-8	64

605	Entecavir in decompensated HBV cirrhosis: the future is looking brighter. 2010 , 52, 147-9	18
604	Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis. 2010 , 52, 176-82	206
603	Long-term use of entecavir in nucleoside-naïve Japanese patients with chronic hepatitis B infection. 2010 , 52, 791-9	95
602	Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues. 2010 , 52, 493-500	96
601	Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B. 2010 , 8, 1079-92	14
600	Antiviral drug resistance: mechanisms and clinical implications. 2010 , 24, 413-37	85
599	Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and/or nonbiological disease-modifying antirheumatic drugs. 2011 , 21, 621-627	60
598	Recent advances in the treatment of chronic hepatitis B. 2011 , 12, 2025-40	23
597	Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation. 2011 , 141, 1212-9	169
596	Current status of liver transplantation for hepatitis B virus. 2011 , 15, 753-64	13
595	Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. 2011 , 9, 274-6	133
594	Emerging pipeline drugs for hepatitis B infection. 2011 , 16, 713-29	20
593	Treatment of chronic hepatitis B: update of the recommendations from the 2007 Italian Workshop. 2011 , 43, 259-65	25
592	Entecavir: a review of its use in the treatment of chronic hepatitis B in patients with decompensated liver disease. 2011 , 71, 2511-29	15
591	Antiviral drugs for HBV liver disease. 2011 , 11, 285-300	19
590	Chronic viral hepatitis in kidney transplantation. 2011 , 7, 156-65	20
589	Cost effectiveness of tenofovir disoproxil fumarate for the treatment of chronic hepatitis B from a Canadian public payer perspective. 2011 , 29, 1075-91	7
588	Discovery and Development of Entecavir. 2011 , 401-416	3

587	Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B. 2011 , 54, 236-42	110
586	Significance of HBV DNA levels at 12 weeks of telbivudine treatment and the 3 years treatment outcome. 2011 , 55, 522-528	30
585	Hepatitis B therapy. 2011 , 8, 275-84	198
584	Management of hepatitis B: Consensus of the Japan Society of Hepatology 2009. 2011 , 41, 1-21	22
583	Recommendation of lamivudine-to-entecavir switching treatment in chronic hepatitis B responders: Randomized controlled trial. 2011 , 41, 505-11	4
582	Hepatitis B virus drug resistance to current nucleos(t)ide analogs: Mechanisms and mutation sites. 2011 , 41, 1017-24	21
581	Management of hepatitis B virus infection in the pre-transplant setting. 2011 , 5, 10-14	
580	Evolution of hepatitis B virus during long-term therapy in patients with chronic hepatitis B. 2011 , 10, 434-440	4
579	The efficacy of anti-viral therapy on hepatitis B virus-associated glomerulonephritis: A systematic review and meta-analysis. 2011 , 10, 165-173	43
578	A cost-effectiveness analysis of different therapies in patients with chronic hepatitis B in Italy. 2011 , 3, 37-46	19
577	Safety and efficacy of entecavir for the treatment of chronic hepatitis B. 2011 , 4, 55-64	22
576	Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil. 2011 , 52, 102-111	4
575	Managing hepatitis B/HIV co-infected: adding entecavir to truvada (tenofovir disoproxil/emtricitabine) experienced patients. 2011 , 25, 1051-6	18
574	Comparison of clevudine and entecavir for treatment-naive patients with chronic hepatitis B virus infection: two-year follow-up data. 2011 , 45, 893-9	19
573	Hepatitis B. 2011 , 367-392	3
572	Entecavir versus lamivudine in the treatment of chronic hepatitis B patients with hepatic decompensation. 2012 , 17, 605-12	12
571	Treatment of chronic hepatitis B: Evolution over two decades. 2011 , 26 Suppl 1, 138-43	130
570	Review article: chronic hepatitis B - anti-viral or immunomodulatory therapy?. <i>Alimentary Pharmacology and Therapeutics</i> , 2011 , 33, 501-13	6.1 31

569	Management options for lamivudine-resistant chronic hepatitis B patients with suboptimal virological suppression by adefovir. <i>Alimentary Pharmacology and Therapeutics</i> , 2011 , 34, 972-81	6.1	14
568	Review article: current antiviral therapy of chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2011 , 34, 1145-58	6.1	66
567	Four-year study of lamivudine and adefovir combination therapy in lamivudine-resistant hepatitis B patients: influence of hepatitis B virus genotype and resistance mutation pattern. 2011 , 18, 206-15		41
566	Impact of hepatitis B e antigen-suppressing mutations on the replication efficiency of entecavir-resistant hepatitis B virus strains. 2011 , 18, 804-14		7
565	Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy. 2011 , 18, 877-83		75
564	Frequency and clinical outcomes of flares related to nucleos(t)ide analogue therapy in patients with chronic hepatitis B. 2011 , 18, e252-7		12
563	Long-term efficacy of entecavir in adefovir-refractory chronic hepatitis B patients with prior lamivudine resistance. 2011 , 18, e475-81		13
562	Hepatitis B virus resistance to antiviral drugs: where are we going?. 2011 , 31 Suppl 1, 111-6		95
561	Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B. 2011 , 31, 676-84		39
560	Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis. 2011 , 8, 393		49
559	Medication nonadherence with long-term management of patients with hepatitis B e antigen-negative chronic hepatitis B. 2011 , 56, 2423-31		44
558	Prevention of hepatitis B virus reactivation in immunosuppressive therapy or chemotherapy. 2011 , 15, 634-640		22
557	De novo combination of lamivudine and adefovir versus entecavir monotherapy for the treatment of naïve HBeAg-negative chronic hepatitis B patients. <i>Hepatology International</i> , 2011 , 5, 671-6	8.8	21
556	Current Management of HBV Antiviral Drug Resistance. 2011 , 10, 120-127		
555	Current Antiviral Therapy of Chronic Hepatitis B: Efficacy and Safety. 2011 , 10, 235-243		21
554	Hepatitis B virus Resistance to Antivirals : Diagnosis and Management. 2011 , 10, 244-254		
553	Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. <i>Hepatology</i> , 2011 , 53, 62-72	11.2	242
552	No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. <i>Hepatology</i> , 2011 , 53, 763-73	11.2	144

551	Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. <i>Hepatology</i> , 2011 , 54, 91-100	11.2	155
550	Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naïve patients with a partial virological response. <i>Hepatology</i> , 2011 , 54, 443-51	11.2	132
549	Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety. 2011 , 106, 1264-71		117
548	Republished paper: Managing HBV in patients with impaired immunity. 2011 , 87, 223-38		2
547	Treatment of hepatitis B in decompensated liver cirrhosis. 2011 , 2011, 918017		23
546	Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 2715-25	5.1	139
545	Emergence of entecavir-resistant mutations in nucleos(t)ide-naïve Japanese patients infected with hepatitis B virus: virological breakthrough is also dependent on adherence to medication. 2011 , 46, 1111-7		22
544	High efficacy of adefovir and entecavir combination therapy in patients with nucleoside-refractory hepatitis B. <i>The Korean Journal of Hepatology</i> , 2012 , 18, 75-83		13
543	Impact of Drug-Resistance Polymerase Mutations on the Replication of HBeAg-Positive and HBeAg-Negative Hepatitis B Virus Strains in Vitro. <i>Hepatitis Monthly</i> , 2012 , 12, 357-60	1.8	4
542	Diagnosis and personalized management of hepatitis B including significance of genotypes. 2012 , 25, 570-7		13
541	Randomized trial of entecavir plus adefovir in patients with lamivudine-resistant chronic hepatitis B who show suboptimal response to lamivudine plus adefovir. 2012 , 56, 2941-7		25
540	Antiviral resistance mutations and genotype-associated amino acid substitutions in treatment-naïve hepatitis B virus-infected individuals from the Indian subcontinent. 2012 , 55, 36-44		31
539	Long-term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901. 2012 , 11, 361-8		46
538	Laboratory evaluation of three regimens of treatment of chronic hepatitis B: tenofovir, entecavir and combination of lamivudine and adefovir. 2012 , 4, 10-6		16
537	Direct acting antivirals for the treatment of chronic viral hepatitis. 2012 , 2012, 478631		5
536	Hepatitis B. 2012 , 540-563		3
535	Virologic responses to add-on adefovir dipivoxil treatment versus entecavir monotherapy in children with lamivudine-resistant chronic hepatitis B. 2012 , 55, 648-52		15
534	Clonal analysis of the quasispecies of antiviral-resistant HBV genomes in patients with entecavir resistance during rescue treatment and successful treatment of entecavir resistance with tenofovir. 2013 , 18, 77-85		9

533	Efficacy and safety of entecavir in clinical practice in treatment-naïve Caucasian chronic hepatitis B patients. 2012 , 24, 535-42	21
532	Long-term therapy with nucleoside/nucleotide analogues for chronic hepatitis B in Asian patients. 2013 , 18, 841-52	13
531	Rescue therapy for lamivudine-resistant chronic hepatitis B: adefovir monotherapy, adefovir plus lamivudine or entecavir combination therapy. 2012 , 51, 1509-15	20
530	A proposal for management of rheumatic disease patients with hepatitis B virus infection receiving immunosuppressive therapy. 2012 , 1	0
529	Hepatitis crónica por virus B. Historia natural y tratamiento. 2012 , 11, 521-528	
528	Management of treatment failure in chronic hepatitis B. 2012 , 56 Suppl 1, S112-22	98
527	Prevalence and significance of Hepatitis B reverse transcriptase mutants in different disease stages of untreated patients. 2012 , 32, 1535-42	18
526	Prediction of response to entecavir therapy in patients with HBeAg-positive chronic hepatitis B based on on-treatment HBsAg, HBeAg and HBV DNA levels. 2012 , 19, 724-31	23
525	Prevention and management of drug resistant hepatitis B virus infections. 2012 , 27, 1432-40	11
524	Tenofovir monotherapy and tenofovir plus entecavir combination as rescue therapy for entecavir partial responders. 2012 , 57, 3011-6	22
523	Selection of chronic hepatitis B therapy with high barrier to resistance. 2012 , 12, 341-53	111
522	The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country. 2012 , 13, 663-76	24
521	Changes in serum histologic surrogate markers and procollagen III N-terminal peptide as independent predictors of HBeAg loss in patients with chronic hepatitis B during entecavir therapy. 2012 , 45, 31-6	5
520	High rates of viral suppression after long-term entecavir treatment of Asian patients with hepatitis B e antigen-positive chronic hepatitis B. 2012 , 10, 1047-1050.e1	12
519	Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management. 2012 , 12, 193-207	73
518	Clinical and virological response to entecavir in HBV-related chronic hepatitis or cirrhosis: data from the clinical practice in a single-centre cohort. 2013 , 18, 87-94	6
517	Lamivudine plus adefovir vs. entecavir in HBeAg-positive hepatitis B with sequential treatment failure of lamivudine and adefovir. 2012 , 32, 1179-85	8
516	Analysis of hepatitis B virus drug-resistant mutant haplotypes by ultra-deep pyrosequencing. 2012 , 18, E404-11	20

515	Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. 2012 , 56, 1006-1011		133
514	Chronic hepatitis B in children and adolescents. 2012 , 57, 885-96		60
513	Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients. 2012 , 57, 508-14		130
512	Hepatitis B virus and human immunodeficiency virus drugs in pregnancy: findings from the Antiretroviral Pregnancy Registry. 2012 , 57, 953-9		59
511	[Hepatitis B virus resistance to entecavir]. 2012 , 139, 228-9		
510	Salting-out homogeneous liquid-liquid extraction approach applied in sample pre-processing for the quantitative determination of entecavir in human plasma by LC-MS. 2012 , 881-882, 119-25		48
509	Antiviral therapies: focus on hepatitis B reverse transcriptase. 2012 , 44, 1060-71		34
508	Randomised clinical trial: the benefit of combination therapy with adefovir and lamivudine for chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 35, 1027-35	6.1	19
507	Considerations for the long-term treatment of chronic hepatitis B with nucleos(t)ide analogs. 2012 , 6, 683-93; quiz 694		18
506	Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B. 2012 , 143, 619-628.e1		120
505	Analysis of hepatitis B virus X gene (HBx) mutants in tissues of patients suffered from hepatocellular carcinoma in China. 2012 , 36, 369-74		18
504	Cost-effectiveness analysis of antiviral treatments for HBeAg-positive chronic hepatitis B in Canada. 2012 , 15, 894-906		16
503	Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B. 2012 , 6, 413-21		10
502	Telbivudine in combination with adefovir versus adefovir monotherapy in HBeAg-positive, lamivudine-resistant chronic hepatitis B. <i>Hepatology International</i> , 2012 , 6, 696-706	8.8	7
501	Chronic hepatitis B infection. 2012 , 16, 347-69		44
500	Long-term impact of entecavir monotherapy in chronic hepatitis B patients with a partial virologic response to entecavir therapy. 2012 , 47, 1362-7		18
499	[Entecavir therapy for patients with hepatitis B virus-related decompensated cirrhosis]. 2012 , 59, 224-31		4
498	Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. <i>Hepatology International</i> , 2012 , 6, 531-61	8.8	768

497	Efficacy of entecavir and adefovir combination therapy for patients with lamivudine- and entecavir-resistant chronic hepatitis B. 2012 , 57, 1358-65		16
496	Partial Response to Entecavir and Tenofovir in Naïve Patients with Chronic Hepatitis B: Clinical Relevance and Management. 2012 , 11, 90-94		4
495	Role of Resistance Testing During Oral Antiviral Therapy of Chronic Hepatitis B. 2012 , 11, 55-64		1
494	Tenofovir plus entecavir as rescue therapy for multidrug-resistant chronic hepatitis B. 2012 , 32, 171-2		4
493	Five years of treatment with adefovir dipivoxil in Chinese patients with HBeAg-positive chronic hepatitis B. 2012 , 32, 137-46		21
492	A review of chronic hepatitis B epidemiology and management issues in selected countries in the Middle East. 2012 , 19, 9-22		31
491	Meta-analysis: oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 35, 674-89	6.1	54
490	Treatment of chronic hepatitis B with nucleos(t)ide analogues. 2012 , 42, 219-25		11
489	Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy. 2012 , 42, 627-36		57
488	Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 35, 1317-25	6.1	113
487	Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3 years. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 35, 1326-35	6.1	42
486	Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir. 2012 , 19, 213-9		36
485	First-line treatment of chronic hepatitis B with entecavir or tenofovir in Real-life Settings: from clinical trials to clinical practice. 2012 , 19, 377-86		99
484	Economic analysis between entecavir and lamivudine for the treatment of chronic hepatitis B in Hong Kong. 2012 , 27, 1167-74		10
483	Adefovir-based combination therapy with entecavir or lamivudine for patients with entecavir-refractory chronic hepatitis B. 2012 , 84, 18-25		12
482	Antiviral efficacy of combination therapy with entecavir and adefovir for entecavir/lamivudine-resistant hepatitis B virus with or without adefovir resistance. 2012 , 84, 424-30		16
481	Antiviral drug resistance testing in patients with chronic hepatitis B. 2012 , 57, 221-31		6
480	A case of anti-GBM glomerulonephritis superimposed on HBV-associated membranous nephropathy. 2013 , 2, 239-247		0

479	Perioperative antiviral therapy for chronic hepatitis B-related hepatocellular carcinoma. 2013 , 12, 251-5		9
478	The efficacy and safety of entecavir in patients with advanced schistosomiasis co-infected with hepatitis B virus. 2013 , 17, e606-9		8
477	A comparison of 4-year entecavir efficacy in nucleos(t)ide analog-naïve and -experienced adult Taiwanese chronic hepatitis B patients. <i>Hepatology International</i> , 2013 , 7, 832-43	8.8	17
476	Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B mono-infection. <i>Hepatology International</i> , 2013 , 7, 327-34	8.8	2
475	Post-transplantation sequential entecavir monotherapy following 1-year combination therapy with hepatitis B immunoglobulin. 2013 , 48, 1401-10		31
474	Combination therapy with a nucleos(t)ide analogue and interferon for chronic hepatitis B: simultaneous or sequential. 2013 , 48, 999-1005		19
473	Entecavir and interferon- β sequential therapy in Japanese patients with hepatitis B e antigen-positive chronic hepatitis B. 2013 , 48, 397-404		19
472	Tertiary Prevention of HBV-related HCC in Asia. 2013 , 12, 157-164		1
471	Resistance is no Longer a Problem with Entecavir and Tenofovir. 2013 , 12, 96-104		
470	Long-term therapy for chronic hepatitis B: hepatitis B virus DNA suppression leading to cirrhosis reversal. 2013 , 28, 912-23		31
469	Virological response and antiviral resistance mutations in chronic hepatitis B subjects experiencing entecavir therapy: an Indian subcontinent perspective. <i>Antiviral Research</i> , 2013 , 98, 209-16	10.8	7
468	Strategic use of lamivudine in the management of chronic hepatitis B. <i>Antiviral Research</i> , 2013 , 100, 435-40.8	10.8	15
467	Hepatitis B virus treatment: Management of antiviral drug resistance. 2013 , 2, 24-28		5
466	Cost-effectiveness of viral hepatitis B & C treatment. 2013 , 27, 973-85		11
465	Molecular virology of chronic hepatitis B and C: parallels, contrasts and impact on drug development and treatment outcome. <i>Antiviral Research</i> , 2013 , 99, 34-48	10.8	7
464	Chronic hepatitis B in children and adolescents: epidemiology and management. 2013 , 15, 311-7		16
463	Treatment of lamivudine-resistant chronic hepatitis B infection: a multicenter retrospective study. 2013 , 48, 196-204		3
462	Do different lamivudine-resistant hepatitis B genotypes carry the same risk of entecavir resistance?. 2013 , 85, 26-33		7

461	Comparison of the efficacy of Lamivudine plus adefovir versus entecavir in the treatment of Lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis. 2013 , 35, 1997-2006		16
460	Clinical outcomes and risk factors of hepatitis B virus recurrence in patients who received prophylaxis with entecavir and hepatitis B immunoglobulin following liver transplantation. 2013 , 45, 3052-6		12
459	Treatment of patients with HBV-related decompensated cirrhosis and liver transplanted patients. 2013 , 17, 451-73		13
458	Nucleoside plus nucleotide analogs and cessation of hepatitis B immunoglobulin after liver transplantation in chronic hepatitis B is safe and effective. 2013 , 58, 67-73		38
457	Hepatitis B virus wild-type and rtN236T populations show similar early HBV DNA decline in adefovir refractory patients on a tenofovir-based regimen. 2013 , 20, 131-40		21
456	Adding adefovir vs. switching to entecavir for lamivudine-resistant chronic hepatitis B (ACE study): a 2-year follow-up randomized controlled trial. 2013 , 33, 244-54		18
455	Optimal management of chronic hepatitis B patients with treatment failure and antiviral drug resistance. 2013 , 33 Suppl 1, 116-24		54
454	A cutting-edge view on the current state of antiviral drug development. 2013 , 33, 1249-77		46
453	Clinical course of patients with insufficient viral suppression during entecavir therapy in genotype C chronic hepatitis B. 2013 , 45, 600-5		14
452	A comparison of clevidine and entecavir for treatment-naïve patients with chronic hepatitis B: results after 2 years of treatment. <i>Hepatology International</i> , 2013 , 7, 106-10	8.8	4
451	Hepatitis B viral factors and treatment responses in chronic hepatitis B. 2013 , 112, 302-11		32
450	Hepatocellular carcinoma: high hepatitis B viral load and mortality in patients treated with transarterial chemoembolization. 2013 , 267, 638-47		24
449	Efficacy and Safety of Telbivudine Compared to Entecavir Among HBeAg+ Chronic Hepatitis B Patients: a Meta-Analysis Study. <i>Hepatitis Monthly</i> , 2013 , 13, e7862	1.8	16
448	Lingmao Formula Combined with Entecavir for HBeAg-Positive Chronic Hepatitis B Patients with Mildly Elevated Alanine Aminotransferase: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. 2013 , 2013, 620230		3
447	A novel estimation of the relative economic value in terms of different chronic hepatitis B treatment options. 2013 , 8, e57900		7
446	Noncompetitive inhibition of hepatitis B virus reverse transcriptase protein priming and DNA synthesis by the nucleoside analog clevidine. 2013 , 57, 4181-9		31
445	Efficacy of adefovir-based combination therapy for patients with Lamivudine- and entecavir-resistant chronic hepatitis B virus infection. 2013 , 57, 6325-32		13
444	Virological response to entecavir reduces the risk of liver disease progression in nucleos(t)ide analogue-experienced HBV-infected patients with prior resistant mutants. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 2154-63	5.1	32

443	Tratamiento del virus de la hepatitis B: Cuáles pacientes deberán ser tratados con los análogos de nucleos(t)idos. 2013 , 2, 83-86	
442	Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B. 2013 , 20, e37-46	66
441	Entecavir for the treatment of patients with hepatitis B virus-related decompensated cirrhosis. 2013 , 14, 1363-9	3
440	Hepatitis B virus treatment: Which patients should be treated with nucleos(t)ide analogue?. 2013 , 2, 21-23	3
439	Two-step evolution of the hepatitis B drug-resistant mutations in a patient who developed primary entecavir resistance. 2013 , 33, 642-6	10
438	Combination nucleos(t)ide analogue as initial treatment for chronic hepatitis B: have we put this to rest?. <i>Hepatology</i> , 2013 , 58, 483-5	11.2 4
437	Response to higher dose of entecavir 1.0 mg daily in patients with partial response to entecavir 0.5 mg daily. 2013 , 47, 461-5	9
436	Slow response to entecavir treatment in treatment-naïve HBV patients is conditioned by immune response rather than by the presence or selection of refractory variants. 2014 , 19, 201-9	9
435	Efficacy of entecavir treatment for up to 5 years in nucleos(t)ide-naïve chronic hepatitis B patients in real life. 2013 , 10, 427-33	46
434	Quantitative hepatitis B surface antigen analysis in hepatitis B e antigen-positive nucleoside-naïve patients treated with entecavir. 2013 , 18, 691-8	15
433	A novel method for the analysis of drug-resistant phenotypes of hepatitis B virus. 2013 , 31, 975-81	3
432	Update on rescue therapies in patients with lamivudine-resistant chronic hepatitis B. 2013 , 7, 777-88	12
431	Efficacy of lamivudine or entecavir against virological rebound after achieving HBV DNA negativity in chronic hepatitis B patients. 2013 , 10, 647-52	7
430	Entecavir and lamivudine therapy for severe acute chronic hepatitis B. 2013 , 5, 545-548	8
429	Efficacy of entecavir switch therapy in chronic hepatitis B patients with incomplete virological response to telbivudine. 2013 , 18, 671-9	8
428	52-week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic hepatitis B. 2013 , 8, e54279	33
427	Disease burden of chronic hepatitis B among immigrants in Canada. 2013 , 27, 137-47	14
426	Comparison of efficacy and safety of tenofovir and entecavir in chronic hepatitis B virus infection: a systematic review and meta-analysis. 2014 , 9, e98865	49

425	Hepatitis B virus infection. 276-294		2
424	Is increasing the dose of Entecavir effective in partial virological responders?. 2014 , 8, 621-5		1
423	Update on hepatitis B virus infection. 2014 , 20, 13293-305		53
422	Entecavir vs lamivudine therapy for naïve patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure. 2014 , 20, 4745-52		26
421	Treatment of chronic hepatitis B in clinical practice with entecavir or tenofovir. 2014 , 20, 7169-80		15
420	Antiviral Therapy of Liver Cirrhosis Related to Hepatitis B Virus Infection. <i>Journal of Clinical and Translational Hepatology</i> , 2014 , 2, 197-201	5.2	15
419	Efficacy and safety of long term entecavir in chronic hepatitis B treatment naïve patients in clinical practice. 2014 , 13, 327-336		56
418	Current developments in nucleoside/nucleotide analogues for hepatitis B. 2014 , 8, 607-22		33
417	Antiviral therapy of chronic hepatitis B. 2014 , 57, 171-80		11
416	Hepatitis B virus drug resistance tools: one sequence, two predictions. 2014 , 57, 232-6		17
415	Partial virological response to three different nucleotide analogues in naïve patients with chronic hepatitis B. 2014 , 13, 602-11		2
414	Drug-resistance associated mutations in polymerase (p) gene of hepatitis B virus isolated from Malaysian HBV carriers. <i>Hepatitis Monthly</i> , 2014 , 14, e13173	1.8	8
413	Contradictory immune response in post liver transplantation hepatitis B and C. 2014 , 2014, 814760		2
412	Clinical implications of hepatitis B virus mutations: recent advances. 2014 , 20, 7653-64		87
411	Efficacy and resistance in de novo combination lamivudine and adefovir dipivoxil therapy versus entecavir monotherapy for the treatment-naïve patients with chronic hepatitis B: a meta-analysis. 2014 , 11, 59		18
410	Molecular virology of hepatitis B virus and targets for antiviral intervention. 2014 , 57, 134-40		15
409	Antiviral effect of entecavir in nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients without virological response at week 24 or 48 of therapy. 2014 , 21, e55-64		13
408	Clinical-pathological analysis of hepatitis B virus recurrence after liver transplantation in Chinese patients. 2014 , 29, 554-60		14

407	Effects of entecavir on peripheral blood lymphocyte profiles in chronic hepatitis B patients with suboptimal responses to adefovir. 2014 , 41, 514-23	3
406	Antihepatitis B therapy: a review of current medications and novel small molecule inhibitors. 2014 , 28, 364-81	16
405	Role of lamivudine with transarterial chemoembolization in the survival of patients with hepatocellular carcinoma. 2014 , 29, 1273-8	19
404	Tenofovir is superior to entecavir for achieving complete viral suppression in HBeAg-positive chronic hepatitis B patients with high HBV DNA. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 39, 629-37	6.1 27
403	Entecavir treatment in kidney transplant recipients infected with hepatitis B. 2014 , 28, 1010-5	19
402	Entecavir plus adefovir versus adefovir plus lamivudine in hepatitis B virus e antigen-positive, lamivudine-resistant chronic hepatitis B. 2014 , 29, 1485-93	4
401	Entecavir plus adefovir combination therapy versus lamivudine add-on adefovir for lamivudine-resistant chronic hepatitis B: A meta-analysis. 2014 , 54, 959-67	1
400	Lamivudine compared with newer antivirals for prophylaxis of hepatitis B core antibody positive livers: a cost-effectiveness analysis. 2014 , 14, 629-34	16
399	Sequential analysis of amino acid substitutions with hepatitis B virus in association with nucleoside/nucleotide analog treatment detected by deep sequencing. 2014 , 44, 678-84	2
398	Nucleos(t)ide analogue therapy for HBV-related HCC after hepatic resection: clinical benefits and unanswered questions. 2014 , 35, 12779-84	19
397	A proposal for management of rheumatic disease patients with hepatitis B virus infection receiving immunosuppressive therapy. 2014 , 24, 1-7	25
396	Prior exposure to lamivudine increases entecavir resistance risk in chronic hepatitis B Patients without detectable lamivudine resistance. 2014 , 58, 1730-7	25
395	Adefovir and lamivudine combination therapy in patients with entecavir-resistant chronic hepatitis B: antiviral responses and evolution of mutations. 2014 , 57, 239-47	5
394	JSH Guidelines for the Management of Hepatitis B Virus Infection. 2014 , 44 Suppl S1, 1-58	120
393	Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B. 2014 , 146, 980-8	127
392	Potential benefit of telbivudine on renal function does not outweigh its high rate of antiviral drug resistance and other adverse effects. 2014 , 146, 15-9	11
391	Long-term efficacy and safety of emtricitabine plus tenofovir DF vs. tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients. 2014 , 60, 715-22	73
390	Similar response to entecavir 0.5 and 1.0 mg in treatment-naïve chronic hepatitis B patients: a case-control study. 2014 , 59, 168-73	7

389	Review article: nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 39, 35-46	6.1	46
388	No resistance to tenofovir disoproxil fumarate through 96 weeks of treatment in patients with lamivudine-resistant chronic hepatitis B. 2014 , 12, 2106-12.e1		33
387	Evaluation of HBV DNA decay kinetics in patients containing both rtM204V/I mutant and wild-type HBV subpopulations during tenofovir DF (TDF) monotherapy or combination therapy with emtricitabine (FTC)/TDF. 2014 , 86, 1473-81		7
386	Successful withdrawal of antiviral treatment in kidney transplant recipients with chronic hepatitis B viral infection. 2014 , 16, 295-303		13
385	Long-term outcomes of chronic hepatitis B virus infection in the era of antiviral therapy in Korea. 2014 , 29, 1005-11		15
384	Management of chronic hepatitis B in children: an unresolved issue. 2014 , 29, 912-9		29
383	Long-term efficacy of entecavir plus adefovir combination therapy versus entecavir monotherapy in adefovir refractory chronic hepatitis B patients with prior lamivudine resistance. 2014 , 57, 8-16		8
382	No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. <i>Hepatology</i> , 2014 , 59, 434-42	11.2	181
381	Population health impact and cost-effectiveness of monitoring inactive chronic hepatitis B and treating eligible patients in Shanghai, China. <i>Hepatology</i> , 2014 , 60, 46-55	11.2	27
380	Management of patients with hepatitis B who require immunosuppressive therapy. 2014 , 11, 209-19		167
379	Efficacy and tolerability of Entecavir for hepatitis B virus infection after hematopoietic stem cell transplantation. 2014 , 3, 450		7
378	Immunosuppression in Patients with Chronic Hepatitis B. 2014 , 13, 235-244		38
377	Changes of HBsAg and HBV DNA levels in Chinese chronic hepatitis B patients after 5 years of entecavir treatment. 2014 , 29, 1028-34		41
376	Entecavir vs. lamivudine in chronic hepatitis B patients with severe acute exacerbation and hepatic decompensation. 2014 , 60, 1127-34		40
375	Hepatitis B virus infection. 2014 , 384, 2053-63		930
374	Management of hepatitis B: our practice and how it relates to the guidelines. 2014 , 12, 16-26		75
373	Management of chronic hepatitis B infection: current treatment guidelines, challenges, and new developments. 2014 , 20, 6262-78		94
372	Epidemiology study of HBV genotypes and antiviral drug resistance in multi-ethnic regions from Western China. 2015 , 5, 17413		24

371	Recent advances in prevention of hepatitis B recurrence after liver transplantation. 2015 , 21, 829-35		12
370	Entecavir allows an unexpectedly high residual replication of HBV mutants resistant to lamivudine. 2015 , 20, 779-87		9
369	Langzeittherapie der HBV-Infektion mit oralen Polymeraseinhibitoren. 2015 , 10, 268-283		
368	Cost-effectiveness analysis of oral anti-viral drugs used for treatment of chronic hepatitis B in Turkey. 2015 , 13, 21		4
367	Tenofovir-based rescue therapy for chronic hepatitis B patients who had failed treatment with lamivudine, adefovir, and entecavir. 2015 , 30, 1514-21		11
366	Current and future antiviral drug therapies of hepatitis B chronic infection. 2015 , 7, 1030-40		42
365	Molecular Mechanisms to Control Post-Transplantation Hepatitis B Recurrence. 2015 , 16, 17494-513		7
364	Short Term Virologic Efficacies of Telbivudine versus Entecavir against Hepatitis B-Related Hepatocellular Carcinoma. 2015 , 2015, 181065		5
363	Impact of prior lamivudine use on the antiviral efficacy and development of resistance to entecavir in chronic hepatitis B patients. <i>Clinical and Molecular Hepatology</i> , 2015 , 21, 131-40	6.9	2
362	Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine. 2015 , 21, 4644-51		18
361	Analysis of minimum target prices for production of entecavir to treat hepatitis B in high- and low-income countries. <i>Journal of Virus Eradication</i> , 2015 , 1, 103-110	2.8	21
360	Lamivudine resistance in children with chronic hepatitis B. 2015 , 7, 896-902		8
359	Real life adherence of chronic hepatitis B patients to entecavir treatment. 2015 , 47, 577-83		15
358	Association Between Level of Hepatitis B Surface Antigen and Relapse After Entecavir Therapy for Chronic Hepatitis B Virus Infection. 2015 , 13, 1984-92.e1		65
357	Prolonged entecavir therapy is not effective for HBeAg seroconversion in treatment-naive chronic hepatitis B patients with a partial virological response. 2015 , 59, 5348-56		7
356	Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. 2015 , 60, 1457-64		196
355	Two-year treatment outcome of chronic hepatitis B infection treated with besifovir vs. entecavir: results from a multicentre study. 2015 , 62, 526-32		38
354	Perioperative antiviral therapy improves safety in patients with hepatitis B related HCC following hepatectomy. 2015 , 15, 1-5		11

353	Incidence of natural resistance mutations in naïve chronic hepatitis B patients: a systematic review and meta-analysis. 2015 , 30, 252-61	23
352	Impact of alpha-fetoprotein on hepatocellular carcinoma development during entecavir treatment of chronic hepatitis B virus infection. 2015 , 50, 785-94	24
351	Prolonged use of tenofovir and entecavir in hepatitis B virus-related cirrhosis. 2015 , 34, 286-91	25
350	Chronic hepatitis B: Are we close to a cure?. 2015 , 47, 836-41	13
349	A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2015 Update. 2015 , 13, 2071-87.e16	75
348	Antiviral treatment for chronic hepatitis B infection in renal transplant recipients. 2015 , 17, 8-13	
347	Transplantation for Hepatitis A and B. 2015 , 105-119	
346	Tenofovir versus entecavir in treatment of chronic hepatitis B virus with severe acute exacerbation. 2015 , 59, 3168-73	21
345	Response to potent anti-HBV agents in chronic hepatitis B and combined effect of HBV reverse transcriptase mutations. 2015 , 567, 22-30	1
344	Entecavir has high efficacy and safety in white patients with chronic hepatitis B and comorbidities. 2015 , 27, 46-54	4
343	Characterization of novel entecavir resistance mutations. 2015 , 63, 546-53	41
342	Monotherapy for hepatitis B infection: a review of treatment options. 2015 , 13, 1457-68	3
341	Recent progress for the synthesis of selected carbocyclic nucleosides. 2015 , 7, 1809-28	18
340	Safe and cost-effective control of post-transplantation recurrence of hepatitis B. 2015 , 45, 38-47	16
339	Cost-Effectiveness Analysis of Alternative Antiviral Strategies for the Treatment of HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B in the United Kingdom. 2015 , 18, 800-9	10
338	Current Management of Chronic Hepatitis B and C in Chronic Kidney Disease. 2015 , 22, 352-60	5
337	Hepatitis B: Working Towards a Cure. 2015 , 17, 35	
336	Partial virological response to entecavir treatment in nucleos(t)ide-naïve patients with HBeAg-positive chronic hepatitis B is not caused by reduced sensitivity. 2015 , 464, 1185-1191	3

335	Quantification of HBsAg in nucleos(t)ide-naïve patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study. 2015 , 62, 56-63		50
334	Cost effectiveness of response-guided therapy with peginterferon in the treatment of chronic hepatitis B. 2015 , 13, 377-385.e5		6
333	Outcomes of patients with chronic hepatitis B who do not meet criteria for antiviral treatment at presentation. 2015 , 13, 193-201.e1		14
332	HBV-DNA level at 6 months of entecavir treatment predicts HBeAg loss in HBeAg-positive chronic hepatitis B patients. 2015 , 114, 308-13		8
331	Recent advances in micro/nanotechnologies for global control of hepatitis B infection. 2015 , 33, 178-190		33
330	Liver disease in kidney transplant recipients. 2015 , 29, 1-7		4
329	Hepatitis B Virus. 2016 , 713-770		
328	Efficacy of entecavir and tenofovir in chronic hepatitis B under treatment in the public health system in southern Brazil. 2016 , 111, 252-7		5
327	KASL clinical practice guidelines: management of chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2016 , 22, 18-75	6.9	141
326	Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy. 2016 , 22, 6484-500		58
325	Overview of hepatitis B virus mutations and their implications in the management of infection. 2016 , 22, 145-54		80
324	A Convenient Truth: Cost of Medications Need Not Be a Barrier to Hepatitis B Treatment. 2016 , 4, 186-90		1
323	Efficacy of Tenofovir-Based Combination Therapy versus Tenofovir Monotherapy in Chronic Hepatitis B Patients Presenting with Suboptimal Responses to Pretreatment: A Meta-Analysis. 2016 , 2016, 7214020		1
322	Treatment for hepatitis B in patients with drug resistance. 2016 , 4, 334		14
321	Treatment Outcomes With First-line Therapies With Entecavir and Tenofovir in Treatment-Naive Chronic Hepatitis B Patients in a Routine Clinical Practice. 2016 , 50, 169-74		18
320	Alternative Therapies for Chronic Hepatitis B Patients With Partial Virological Response to Standard Entecavir Monotherapy. 2016 , 50, 338-44		2
319	Randomized, controlled trial of entecavir versus placebo in children with hepatitis B envelope antigen-positive chronic hepatitis B. <i>Hepatology</i> , 2016 , 63, 377-87	11.2	59
318	Hepatitis B virus in children: More therapeutic options-but unknown and known unknowns still present. <i>Hepatology</i> , 2016 , 63, 360-2	11.2	1

317	Entecavir plus tenofovir combination therapy in patients with multidrug-resistant chronic hepatitis B: results of a multicentre, prospective study. 2016 , 36, 1108-15		18
316	Prediction of virologic response to tenofovir mono-rescue therapy for multidrug resistant chronic hepatitis B. 2016 , 88, 1027-34		8
315	Flares during long-term entecavir therapy in chronic hepatitis B. 2016 , 31, 1882-1887		7
314	A five years study of antiviral effect of entecavir in Chinese chronic hepatitis B patients. 2016 , 6, 28779		3
313	Chronic Hepatitis B, C, and D. 2016 , 4,		0
312	Entecavir plus tenofovir combination therapy for chronic hepatitis B in patients with previous nucleos(t)ide treatment failure. <i>Hepatology International</i> , 2016 , 10, 779-88	8.8	17
311	Evolution of entecavir-resistant hepatitis B virus during entecavir and adefovir dipivoxil combination therapy. 2016 , 11, 117-123		2
310	Dynamics of Genotypic Mutations of the Hepatitis B Virus Associated With Long-Term Entecavir Treatment Determined With Ultradeep Pyrosequencing: A Retrospective Observational Study. 2016 , 95, e2614		4
309	Umbilical Cord-Derived Mesenchymal Stem Cell Transplantation in Hepatitis B Virus Related Acute-on-Chronic Liver Failure Treated with Plasma Exchange and Entecavir: a 24-Month Prospective Study. 2016 , 12, 645-653		42
308	Comparison of entecavir and lamivudine in preventing HBV reactivation in lymphoma patients undergoing chemotherapy: a meta-analysis. 2016 , 38, 1035-43		17
307	Entecavir safety and effectiveness in a national cohort of treatment-naïve chronic hepatitis B patients in the US - the ENUMERATE study. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 43, 134-44 ^{6.1}	6.1	49
306	Hepatitis B virus: new therapeutic perspectives. 2016 , 36 Suppl 1, 85-92		35
305	Detection of Anti-Hepatitis B Virus Drug Resistance Mutations Based on Multicolor Melting Curve Analysis. 2016 , 54, 2661-2668		4
304	Treatment of Hepatitis B: A Concise Review. 2016 , 7, e190		19
303	Review article: novel therapies for hepatitis B virus cure - advances and perspectives. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 44, 213-22	6.1	39
302	Clinical implication of serum Wisteria floribunda agglutinin positive Mac-2-binding protein level on hepatitis B e-antigen loss or seroconversion in hepatitis B e-antigen positive patients. 2016 , 46, 1065-1073		10
301	Approved Antiviral Drugs over the Past 50 Years. 2016 , 29, 695-747		731
300	Analysis of baseline hepatitis B virus DNA levels in chronic hepatitis B patients with non-hematological malignancies prior to the initiation of cancer chemotherapy. 2016 , 5, 165-170		

299	Clinical course of partial virological responders under prolonged entecavir monotherapy in patients with chronic hepatitis B. 2016 , 88, 252-9		1
298	Use of telbivudine in kidney transplant recipients with chronic hepatitis B virus infection: A preliminary experience. 2016 , 21, 438-41		4
297	Association Between Level of Fibrosis, Rather Than Antiviral Regimen, and Outcomes of Patients With Chronic Hepatitis B. 2016 , 14, 1647-1656.e6		29
296	Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial. 2016 , 65, 852-60		62
295	Design and synthesis of pyridine-pyrazole-sulfonate derivatives as potential anti-HBV agents. 2016 , 7, 832-836		14
294	New therapeutic agents for chronic hepatitis B. 2016 , 16, e10-21		49
293	Prevention and management of hepatitis B virus reactivation in cancer patients. <i>Hepatology International</i> , 2016 , 10, 407-14	8.8	16
292	Efficacy of tenofovir-based rescue therapy in patients with lamivudine-resistant hepatitis B virus: A systematic review and meta-analysis. 2016 , 40, 447-56		4
291	The suppressive effect of nucleos(t)ide analogue treatment on the incidence of hepatocellular carcinoma in chronic hepatitis B patients. 2016 , 31, 546-52		15
290	Hepatitis B: 50 years after the discovery of Australia antigen. 2016 , 23, 5-14		21
289	Antiviral therapy in chronic hepatitis B viral infection during pregnancy: A systematic review and meta-analysis. <i>Hepatology</i> , 2016 , 63, 319-33	11.2	209
288	Off-treatment efficacy of 3-year nucleos(t)ide analogues in chronic hepatitis B patients. 2016 , 32, 10-5		1
287	Emerging drugs for the treatment of hepatitis B. 2016 , 21, 183-93		8
286	A review of supportive care and recommended preventive approaches for patients with chronic lymphocytic leukemia. 2016 , 9, 235-44		6
285	Lymphoproliferative Disease and Hepatitis B Reactivation: Challenges in the Era of Rapidly Evolving Targeted Therapy. 2016 , 16, 5-11		11
284	A comparison of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive patients: a prospective cohort study in China. 2016 , 22, 287.e1-9		14
283	An evaluation of entecavir for the treatment of chronic hepatitis B infection in adults. 2016 , 10, 177-86		7
282	Tenofovir rescue therapy in chronic hepatitis B patients who failed previous nucleoside analogue treatment. <i>Hepatology International</i> , 2016 , 10, 302-9	8.8	2

281	Pharmacotherapeutic options for hepatitis B. 2016 , 17, 355-67		10
280	Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. <i>Hepatology International</i> , 2016 , 10, 1-98	8.8	1288
279	The Basis for Antiviral Therapy: Drug Targets, Cross-Resistance, and Novel Small Molecule Inhibitors. <i>Molecular and Translational Medicine</i> , 2016 , 303-324	0.4	3
278	The effect of plasma exchange on entecavir-treated chronic hepatitis B patients with hepatic de-compensation and acute-on-chronic liver failure. <i>Hepatology International</i> , 2016 , 10, 462-9	8.8	40
277	Combined Analysis of the Prevalence of Drug-Resistant Hepatitis B Virus in Antiviral Therapy-Experienced Patients in Europe (CAPRE). 2016 , 213, 39-48		25
276	Postoperative Antiviral Therapy With Nucleos(t)ide Analogs in Patients With Hepatitis B Virus--Related Hepatocellular Carcinoma. 2017 , 265, e46-e47		6
275	Efficacy and safety of entecavir versus tenofovir treatment in chronic hepatitis B patients: A randomized controlled trial. 2017 , 47, E161-E168		30
274	Antiviral therapies for managing viral hepatitis in lymphoma patients. 2017 , 18, 363-376		9
273	Hepatitis B virus long-term impact of antiviral therapy nucleot(s)ide analogues (NUCs). 2017 , 37 Suppl 1, 45-51		37
272	Economic Analysis and Budget Impact of Tenofovir and Entecavir in the First-Line Treatment of Hepatitis B Virus in Italy. 2017 , 15, 479-490		7
271	Entecavir for patients with lamivudine-resistant chronic hepatitis B virus infection. 2017 ,		1
270	Validation of PAGE-B model in Asian chronic hepatitis B patients receiving entecavir or tenofovir. 2017 , 37, 1788-1795		31
269	Efficacy and Safety of Lamivudine Versus Entecavir for Treating Chronic Hepatitis B Virus-related Acute Exacerbation and Acute-on-Chronic Liver Failure: A Systematic Review and Meta-Analysis. 2017 , 51, 539-547		9
268	Current treatment guidelines of chronic hepatitis B: The role of nucleos(t)ide analogues and peginterferon. 2017 , 31, 299-309		41
267	Resistance mutations of hepatitis B virus in entecavir-refractory patients. 2017 , 1, 110-121		13
266	A different inhibitor is required for overcoming entecavir resistance: a comparison of four rescue therapies in a retrospective study. 2017 , 83, 2259-2265		2
265	HBV Therapy and the Problem of Drug Resistance. 2017 , 3-20		1
264	Evolutionary trends of resistance mutational patterns of HBV reverse transcriptase over years (2002-2012) of different treatment regimens: The legacy of lamivudine/adefovir combination treatment. <i>Antiviral Research</i> , 2017 , 143, 62-68	10.8	5

263	Comparison of the long-term efficacy between entecavir and tenofovir in treatment-naïve chronic hepatitis B patients. 2017 , 17, 39		27
262	Correction. <i>Hepatology</i> , 2017 , 65, 1427	11.2	0
261	Entecavir maleate versus entecavir in Chinese chronic hepatitis B predominantly genotype B or C: Results at week 144. 2017 , 24, 877-884		2
260	Analysis of the prevalence of drug-resistant hepatitis B virus in patients with antiviral therapy failure in a Chinese tertiary referral liver centre (2010-2014). 2017 , 8, 74-81		12
259	Recapitulation of treatment response patterns in a novel humanized mouse model for chronic hepatitis B virus infection. 2017 , 502, 63-72		12
258	Tenofovir alafenamide demonstrates broad cross-genotype activity against wild-type HBV clinical isolates and maintains susceptibility to drug-resistant HBV isolates in vitro. <i>Antiviral Research</i> , 2017 , 139, 25-31	10.8	24
257	Cost-Effectiveness Comparison Between the Response-Guided Therapies and Monotherapies of Nucleos(t)ide Analogues for Chronic Hepatitis B Patients in China. 2017 , 37, 233-247		2
256	Comparison of 208-week sequential therapy with telbivudine and entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24 weeks of Peg-IFN α therapy: An open-labelled, randomized, controlled, "real-life" trial. 2017 , 24 Suppl 1, 36-42		5
255	Reply. <i>Hepatology</i> , 2017 , 66, 1706	11.2	
254	Development of a digital droplet PCR assay to measure HBV DNA in patients receiving long-term TDF treatment. 2017 , 249, 189-193		7
253	Compartmental HBV evolution and replication in liver and extrahepatic sites after nucleos(t)ide analogue therapy in chronic hepatitis B carriers. 2017 , 94, 8-14		16
252	Effects of antiviral therapy in patients with chronic hepatitis B and cirrhosis. 2017 , 11, 1095-1104		15
251	Comparison of the Efficacy of Tenofovir Versus Tenofovir plus Entecavir in the Treatment of Chronic Hepatitis B in Patients With Poor Efficacy of Entecavir: A Systematic Review and Meta-analysis. 2017 , 39, 1870-1880		9
250	Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation-a position paper. 2017 , 23, 935-940		56
249	Tenofovir versus tenofovir plus entecavir for chronic hepatitis B with lamivudine resistance and entecavir resistance. 2017 , 24, 141-147		22
248	Long-term outcomes of hepatitis B virus-related cirrhosis treated with nucleos(t)ide analogs. 2017 , 116, 512-521		20
247	Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study. 2017 , 66, 11-18		41
246	Week 4 viral load predicts long-term suppression of hepatitis B virus DNA during antiviral therapy: improving hepatitis B treatment in the real world. 2017 , 47, 50-56		1

245	No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg- patients with chronic hepatitis B after 8 years of treatment. 2017 , 24, 68-74		77
244	Hepatitis B and D. 2017 , 584-627		
243	Guideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update). <i>Journal of Clinical and Translational Hepatology</i> , 2017 , 5, 297-318	5.2	136
242	Cost-Effectiveness and Clinical Impact of Antiviral Strategies of HBeAg-Positive and -Negative Chronic Hepatitis B. 2017 , 16, 358-365		3
241	Efficacy of Real-world Entecavir Therapy in Treatment-naïve Chronic Hepatitis B Patients. 2017 , 130, 2190-2197		6
240	Recent Epidemiological Changes in Infectious Diseases. 2017 , 511-552		
239	Immune Tolerant Chronic Hepatitis B: The Unrecognized Risks. 2017 , 9,		35
238	Hepatitis B Virus Immunopathology, Model Systems, and Current Therapies. 2017 , 8, 436		17
237	Upcoming pharmacological developments in chronic hepatitis B: can we glimpse a cure on the horizon?. 2017 , 17, 168		12
236	Pediatric hepatitis B treatment. 2017 , 5, 37		12
235	Management of Antiviral Resistance in Chronic Hepatitis B. 2017 , 11, 189-195		29
234	Hepatitis B in renal transplant patients. 2017 , 9, 1054-1063		11
233	Long-term real-world entecavir therapy in treatment-naïve hepatitis B patients: base-line hepatitis B virus DNA and hepatitis B surface antigen levels predict virologic response. <i>Korean Journal of Internal Medicine</i> , 2017 , 32, 636-646	2.5	10
232	Genotyping of HBV and tracking of resistance mutations in treatment-naïve patients with chronic hepatitis B. 2017 , 10, 201-207		12
231	Efficacy of tenofovir-based rescue therapy for chronic hepatitis B patients with resistance to lamivudine and entecavir. <i>Clinical and Molecular Hepatology</i> , 2017 , 23, 230-238	6.9	11
230	Trends in hepatitis B virus resistance to nucleoside/nucleotide analogues in North China from 2009-2016: A retrospective study. 2018 , 52, 201-209		17
229	Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. <i>Hepatology</i> , 2018 , 67, 1560-1599	11.2	1460
228	Antiviral Agents. 2018 , 1551-1567.e6		3

227	Nucleos(t)ide Therapy and Long-Term Outcomes. 2018 , 193-217	1
226	Pharmacokinetic evaluation of besifovir for the treatment of HBV infection. 2018 , 14, 101-106	2
225	Molecular Virology and Life Cycle. 2018 , 1-23	1
224	Chronic Hepatitis B Infection: A Review. 2018 , 319, 1802-1813	266
223	Chronic lymphocytic leukemia and infection risk in the era of targeted therapies: Linking mechanisms with infections. 2018 , 32, 387-399	34
222	Current antiviral drugs and their analysis in biological materials - Part II: Antivirals against hepatitis and HIV viruses. 2018 , 147, 378-399	28
221	Delayed viral suppression during antiviral therapy is associated with increased hepatocellular carcinoma rates in HBeAg-positive high viral load chronic hepatitis B. 2018 , 25, 552-560	7
220	Tenofovir, entecavir, and lamivudine in patients with severe acute exacerbation and hepatic decompensation of chronic hepatitis B. 2018 , 50, 163-167	7
219	Evolution of drug-resistant mutations in HBV genomes in patients with treatment failure during the past seven years (2010-2016). 2018 , 54, 41-47	9
218	Development of tenofovir disoproxil fumarate resistance after complete viral suppression in a patient with treatment-naïve chronic hepatitis B: A case report and review of the literature. 2018 , 24, 1919-1924	17
217	Viral Hepatitis in Children. 2018 , 1015-1028.e3	0
216	Concomitant food intake does not affect the efficacy of entecavir in chronic hepatitis B patients with virological response: a randomized, multicenter, noninferiority trial. 2018 , 12, 3767-3774	
215	Long-term Outcomes in Patients with HBV Treated with Antiviral Agents. 2018 , 17, 502-510	1
214	Clinical Implications of Hepatitis B Virus RNA and Covalently Closed Circular DNA in Monitoring Patients with Chronic Hepatitis B Today with a Gaze into the Future: The Field Is Unprepared for a Sterilizing Cure. 2018 , 9,	7
213	Chinese Herbal Medicine Combined with Entecavir for HBeAg Positive Chronic Hepatitis B: Study Protocol for a Multi-Center, Double-Blind Randomized-Controlled Trial. 2018 , 24, 653-660	5
212	Discovery of the Novel Entecavir-Resistant Hepatitis B Virus Reverse Transcriptase A181C Substitution From an Integrated Genotypic Analysis. 2018 , 2, 1123-1135	2
211	Switching to tenofovir vs continuing entecavir for hepatitis B virus with partial virologic response to entecavir: a randomized controlled trial. 2018 , 25, 1321-1330	14
210	Population Health And Economic Impacts Of Reaching Chronic Hepatitis B Diagnosis And Treatment Targets In The US. 2018 , 37, 1033-1040	7

209	No Resistance to Tenofovir Alafenamide Detected through 96 Weeks of Treatment in Patients with Chronic Hepatitis B Infection. 2018 , 62,	27
208	An Overview of Hepatitis B Virus Surface Antigen Secretion Inhibitors. 2018 , 9, 662	12
207	Hepatitis B virus infection. 2018 , 4, 18035	250
206	Hepatitis B. 2018 , 395-420	
205	Strategies for the treatment of HBV/HDV. 2018 , 833, 379-391	12
204	Prevention Strategies for Hepatocellular Carcinoma. <i>Molecular and Translational Medicine</i> , 2019 , 255-289.4	1
203	Management of Virologic Failure in Patients with Chronic Hepatitis B Treated with Nucleos(t)ide Analogues. 2019 , 18, 363-369	
202	KASL clinical practice guidelines for management of chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2019 , 25, 93-159	6.9 87
201	Antiviral Consideration for Transplantation Including Drug Resistance. 2019 , 953-975	1
200	Current perspectives into the evaluation and management of hepatitis B: a review. 2019 , 8, 361-369	6
199	Long-term data on entecavir treatment for treatment-naïve or lamivudine-resistant chronic hepatitis B infection in kidney transplant recipients. 2019 , 21, e13143	3
198	Hepatitis B in Pregnant Women and their Infants. 2019 , 23, 451-462	7
197	WHO Guidelines for Prevention, Care and Treatment of Individuals Infected with HBV: A US Perspective. 2019 , 23, 417-432	17
196	Association of virological breakthrough and clinical outcomes in entecavir-treated HBeAg-positive chronic hepatitis B. 2019 , 14, e0221958	1
195	Lower Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir in Patients With Chronic Hepatitis B. 2019 , 5, 915	
194	Hepatitis B virus mutation pattern rtL180M+A181C+M204V may contribute to entecavir resistance in clinical practice. 2019 , 8, 354-365	12
193	[Hepatitis B virus infection: Natural history, clinical manifestations and therapeutic approach]. 2019 , 40, 590-598	0
192	Treatment Outcome and Renal Safety of 3-Year Tenofovir Disoproxil Fumarate Therapy in Chronic Hepatitis B Patients with Preserved Glomerular Filtration Rate. 2019 , 13, 93-103	12

191	Prevalence of the entecavir-resistance-inducing mutation rtA186T in a large cohort of Chinese hepatitis B virus patients. <i>Antiviral Research</i> , 2019 , 164, 131-138	10.8	7
190	Switching to tenofovir disoproxil fumarate vs continuing treatment in patients with chronic hepatitis B who maintain long-term virological response to entecavir therapy: A randomized trial. 2019 , 91, 1295-1300		7
189	Liver Disease Among Renal Transplant Recipients. 2019 , 539-565		
188	Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition. 2019 , 7, 322		60
187	Risk factors for resistance development against lamivudine during long-term treatment of chronic hepatitis B virus infections. 2019 , 31, 845-852		2
186	Taiwan consensus statement on the management of chronic hepatitis B. 2019 , 118, 7-38		25
185	Hepatitis B Treatment: What We Know Now and What Remains to Be Researched. 2019 , 3, 8-19		38
184	Clinical and virological outcomes of entecavir therapy in patients with chronic hepatitis B: A real life experience. 2019 , 25, 12-16		1
183	Effectiveness and safety of switching to entecavir hepatitis B patients developing kidney dysfunction during tenofovir. 2019 , 39, 484-493		8
182	Fibrosis-matched outcomes between chronic hepatitis B patients with drug-induced virological response and inactive carriers. 2019 , 39, 81-89		1
181	Outcomes of Long-term Treatment of Chronic HBV Infection With Entecavir or Other Agents From a Randomized Trial in 24 Countries. 2020 , 18, 457-467.e21		27
180	Tenofovir monotherapy versus tenofovir plus entecavir combination therapy in HBeAg-positive chronic hepatitis patients with partial virological response to entecavir. 2020 , 92, 302-308		2
179	Entecavir resistance mutations rtL180M/T184L/M204V combined with rtA200V lead to tenofovir resistance. 2020 , 40, 83-91		11
178	Hepatitis B virus genotype D in T2DM: A report from a tertiary care centre, Chennai. 2020 , 17, 100160		
177	Hepatitis víicas: virus de la hepatitis A, B y E. 2020 , 13, 237-244		
176	The clinical efficacy and adverse effects of Entecavir plus Thymosin alpha-1 combination therapy versus Entecavir Monotherapy in HBV-related cirrhosis: a systematic review and meta-analysis. 2020 , 20, 348		2
175	An expert review on the use of tenofovir alafenamide for the treatment of chronic hepatitis B virus infection in Asia. 2020 , 55, 811-823		19
174	Hepatitis B virus X gene mutants emerge during antiviral therapy and increase cccDNA levels to compensate for replication suppression. <i>Hepatology International</i> , 2020 , 14, 973-984	8.8	2

173	Tenofovir-based combination therapy or monotherapy for multidrug-resistant chronic hepatitis B: Long-term data from a multicenter cohort study. 2020 , 27, 1306-1318		1
172	COLD-PCR Method for Early Detection of Antiviral Drug-Resistance Mutations in Treatment-Naive Children with Chronic Hepatitis B. 2020 , 10,		4
171	Application of EASL 2017 criteria for switching hepatitis B patients from tenofovir disoproxil to entecavir or tenofovir alafenamide. 2020 , 52, 1164-1169		6
170	Revisiting HBV resistance to entecavir with a phenotypic approach. <i>Antiviral Research</i> , 2020 , 181, 104869-108	10.8	1
169	Efficacy and cost-effectiveness of antiviral regimens for entecavir-resistant hepatitis B: A systematic review and network meta-analysis. 2020 , 19, 507-514		
168	Entecavir-resistant hepatitis B virus decreases surface antigenicity: A full genome and functional characterization. 2020 , 40, 1564-1577		2
167	Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study. 2020 , 69, 2214-2222		10
166	Coevolution analysis of amino-acids reveals diversified drug-resistance solutions in viral sequences: a case study of hepatitis B virus. 2020 , 6, veaa006		2
165	Developing a sensitive HBV genotyping assay for HBV DNA suppressed patients using both DNA and RNA sequencing. 2020 , 92, 3420		2
164	Hepatitis B virus mutation pattern rtA181S+T184I+M204I may contribute to multidrug resistance in clinical practice: Analysis of a large cohort of Chinese patients. <i>Antiviral Research</i> , 2020 , 180, 104852	10.8	3
163	Tenofovir disoproxil fumarate for patients with chronic hepatitis B who suboptimal response to non-tenofovir disoproxil fumarate nucleos(t)ide analogs therapy. 2020 , 7, 207-213		0
162	7-Deaza-7-fluoro modification confers on 4Ncyano-nucleosides potent activity against entecavir/adefovir-resistant HBV variants and favorable safety. <i>Antiviral Research</i> , 2020 , 176, 104744	10.8	6
161	Approach to the patient with chronic hepatitis B and decompensated cirrhosis. 2020 , 40 Suppl 1, 22-26		5
160	Pharmacotherapy options for managing hepatitis B in children. 2021 , 22, 449-467		0
159	Prophylaxis, diagnosis and therapy of infections in patients undergoing high-dose chemotherapy and autologous haematopoietic stem cell transplantation. 2020 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). 2021 , 100, 321-336		14
158	Characterization of Hepatitis B virus polymerase mutations A194T and CYEI and tenofovir disoproxil fumarate or tenofovir alafenamide resistance. 2021 , 28, 30-39		4
157	Stability Analysis and Cauchy Matrix of a Mathematical Model of Hepatitis B Virus with Control on Immune System near Neighborhood of Equilibrium Free Point. 2021 , 13, 166		4
156	The 48-week safety and therapeutic effects of tenofovir alafenamide in hbv-related acute-on-chronic liver failure: A prospective cohort study. 2021 , 28, 592-600		2

155	Maintaining Antiviral Efficacy after Switching to Generic Entecavir 1 mg for Antiviral-resistant Chronic Hepatitis B. 2021 , 77, 22-29		1
154	Distinctive HBV Replication Capacity and Susceptibility to Tenofovir Induced by a Polymerase Point Mutation in Hepatoma Cell Lines and Primary Human Hepatocytes. 2021 , 22,		1
153	The NTCP p.Ser267Phe Variant Is Associated With a Faster Anti-HBV Effect on First-Line Nucleos(t)ide Analog Treatment. 2021 , 12, 616858		1
152	Trends and strategies to combat viral infections: A review on FDA approved antiviral drugs. 2021 , 172, 524-541		38
151	Position statement on the use of Tenofovir Alafenamide for the treatment of chronic Hepatitis B Virus infection in Africa. 2020 , 11, 57-63		
150	Hepatitis B Virus Infection in Children. 2021 , 285-303		
149	Prophylactic antiviral therapy for hepatitis B virus surface antigen-positive patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy. 2021 , 112, 1943-1954		3
148	Transaminase Elevations during Treatment of Chronic Hepatitis B Infection: Safety Considerations and Role in Achieving Functional Cure. 2021 , 13,		1
147	Entecavir resistance in a patient with treatment-naïve HBV: A case report. 2021 , 14, 113		5
146	Spontaneous reactivation of hepatitis B virus with a frameshift mutation in the precore region in an elderly hepatitis B virus carrier with lifestyle-related diseases. 2021 , 14, 1202-1210		0
145	Cost-Effectiveness of One-Time Universal Screening for Chronic Hepatitis B Infection in Adults in the United States. 2021 ,		8
144	Global prevalence and phylogeny of hepatitis B virus (HBV) drug and vaccine resistance mutations. 2021 , 28, 1110-1120		1
143	Multilocus drug resistance mutation analysis in 148 HBV patients in northern Henan Province of China.		1
142	Entecavir Monotherapy Prevents Hepatitis B Virus Recurrence After Liver Transplant for Chronic Hepatitis B Patients: A Long-Term Retrospective Study. 2021 , 53, 1700-1706		1
141	Molecular and computational analysis of natural drug resistance mutations among Moroccan chronic hepatitis B carriers. 2021 , 23, 101197		
140	The Application of Dynamic Uncertain Causality Graph Based Diagnosis and Treatment Unification Model in the Intelligent Diagnosis and Treatment of Hepatitis B. 2021 , 13, 1185		1
139	Effectiveness of Tenofovir Alafenamide in Chronic Hepatitis B Patients with Normal Alanine Aminotransferase and Positive Hepatitis B Virus DNA.. <i>Journal of Clinical and Translational Hepatology</i> , 2022 , 10, 112-119	5.2	1
138	Progress and challenges in the comprehensive management of chronic viral hepatitis: Key ways to achieve the elimination. 2021 , 27, 4004-4017		1

137	Real-life data of tenofovir disoproxil fumarate and tenofovir alafenamide fumarate in the patients with chronic hepatitis B: a single-center experience. 2021 , 3, 239-245		
136	S3-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion [(AWMF-Register-Nr. 021-11). 2021 , 59, 691-776		9
135	Strategies to Inhibit Hepatitis B Virus at the Transcript Level. 2021 , 13,		1
134	Evolution and phenotypic characterization of whole HBV genome in compliant patients experiencing unexplained entecavir treatment failure. <i>Antiviral Research</i> , 2021 , 192, 105106	10.8	2
133	Randomised clinical trial: 48 weeks of treatment with tenofovir amibufenamide versus tenofovir disoproxil fumarate for patients with chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 54, 1134-1149	6.1	1
132	Guidelines for Prevention and Treatment of Chronic Hepatitis B. <i>Journal of Clinical and Translational Hepatology</i> , 2021 , 9, 769-791	5.2	5
131	Asociación Mexicana de Hepatología A.C. Clinical guideline on hepatitis B. 2021 , 86, 403-432		
130	Association between HBs Ag quantification and the risk of hepatocellular carcinoma in patients treated with tenofovir disoproxil fumarate or entecavir. 2021 , 100, e27417		
129	Asociación Mexicana de Hepatología A.C. Clinical guideline on hepatitis B. 2021 , 86, 403-403		
128	Opioid use disorder and Chronic Hepatitis B. 2021 , 97-123		
127	Evaluation of oral antiviral treatments for chronic Hepatitis B using fuzzy PROMETHEE. 2021 , 249-260		
126	Hepatitis B and Hepatitis D Infections in the Transplant Setting. 2021 , 927-950		
125	Nucleos(t)ide Therapy and Long-Term Outcomes. 2021 , 287-318		
124	Molecular Prevalence and Causes of Hepatitis B Virus Infection in District Bannu Khyber Pakhtunkhwa, Pakistan. 2021 , 001-006		
123	Long-term efficacy and safety of nucleos(t)ides analogues in patients with chronic hepatitis B. 2021 , 8, 2049936120985954		5
122	Hepatitis B Virus Drug Resistance. 2017 , 1227-1242		5
121	Present and Future Therapies for Chronic Hepatitis B. 2020 , 1179, 137-186		24
120	Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and/or nonbiological disease-modifying antirheumatic drugs. 2011 , 21, 621-7		38

119	Hepatitis B Virus and Hepatitis Delta Virus. 2010 , 2059-2086		3
118	Hepatitis B Virus and Hepatitis Delta Virus. 2015 , 1815-1839.e7		4
117	Entecavir resistance mutations rtL180M/T184L/M204V combined with rtA200V lead to tenofovir resistance.		1
116	Susceptibility Test Methods: Viruses. 1913-1931		1
115	Phenotypic and Genotypic Antiviral Susceptibility Testing. 201-227		1
114	Pre-existing mutations in reverse transcriptase of hepatitis B virus in treatment-naïve Chinese patients with chronic hepatitis B. 2015 , 10, e0117429		15
113	Cost-Effectiveness and Cost Thresholds of Generic and Brand Drugs in a National Chronic Hepatitis B Treatment Program in China. 2015 , 10, e0139876		18
112	Genetic Evidence for Genotoxic Effect of Entecavir, an Anti-Hepatitis B Virus Nucleotide Analog. 2016 , 11, e0147440		8
111	On-treatment HBV DNA dynamics predict virological breakthrough in entecavir-treated HBeAg-positive chronic hepatitis B. 2017 , 12, e0174046		4
110	The Molecular and Structural Basis of HBV-resistance to Nucleos(t)ide Analogs. <i>Journal of Clinical and Translational Hepatology</i> , 2014 , 2, 202-11	5.2	14
109	Free energy profile of permeation of Entecavir through Hepatitis B virus capsid studied by molecular dynamics calculation. 2020 , 92, 1585-1594		2
108	[Interferon-based versus direct antiviral therapy in patients with chronic hepatitis B]. 2011 , 152, 869-74		0
107	[Interdisciplinary aspects of and new drugs for chronic hepatitis B]. 2013 , 154, 1142-50		1
106	Guidelines for the management of hepatitis B virus infection. 2013 , 54, 402-472		3
105	KASL Clinical Practice Guidelines: Management of chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2012 , 18, 109-62	6.9	129
104	Clinical impacts of hazardous alcohol use and obesity on the outcome of entecavir therapy in treatment-naïve patients with chronic hepatitis B infection. <i>Clinical and Molecular Hepatology</i> , 2012 , 18, 195-202	6.9	11
103	Options for the management of antiviral resistance during hepatitis B therapy: reflections on battles over a decade. <i>Clinical and Molecular Hepatology</i> , 2013 , 19, 195-209	6.9	23
102	Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide-naïve chronic hepatitis B patients in Korea: data from the clinical practice setting in a single-center cohort. <i>Clinical and Molecular Hepatology</i> , 2014 , 20, 261-6	6.9	10

101	Long-term outcomes of two rescue therapies in lamivudine-refractory patients with chronic hepatitis B: combined lamivudine and adefovir, and 1-mg entecavir. <i>Clinical and Molecular Hepatology</i> , 2014 , 20, 267-73	6.9	5
100	Personalized treatment of hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2015 , 21, 1-6	6.9	20
99	Efficacy of prolonged entecavir monotherapy in treatment-naïve chronic hepatitis B patients exhibiting a partial virologic response to entecavir. <i>Clinical and Molecular Hepatology</i> , 2015 , 21, 24-31	6.9	16
98	Comparison of the clinical outcomes between antiviral-naïve patients treated with entecavir and lamivudine-resistant patients receiving adefovir add-on lamivudine combination treatment. <i>Clinical and Molecular Hepatology</i> , 2016 , 22, 350-358	6.9	1
97	Clinical characteristics of patients with chronic hepatitis B who developed genotypic resistance to entecavir: Real-life experience. <i>Clinical and Molecular Hepatology</i> , 2017 , 23, 323-330	6.9	6
96	[Clinical efficacy of entecavir therapy and factors associated with treatment response in naive chronic hepatitis B patients]. <i>The Korean Journal of Hepatology</i> , 2009 , 15, 446-53		2
95	[Efficacy and predictors of the virologic response to entecavir therapy in nucleoside-naive patients with chronic hepatitis B]. <i>The Korean Journal of Hepatology</i> , 2010 , 16, 57-65		10
94	[Genotypic resistance to entecavir in chronic hepatitis B patients]. <i>The Korean Journal of Hepatology</i> , 2010 , 16, 147-57		2
93	Pretreatment serum HBsAg-to-HBV DNA ratio predicts a virologic response to entecavir in chronic hepatitis B. <i>The Korean Journal of Hepatology</i> , 2011 , 17, 268-73		7
92	Hepatitis B virus infection and renal transplantation. 2010 , 16, 3878-87		16
91	Effects of telbivudine and entecavir for HBeAg-positive chronic hepatitis B: a meta-analysis. 2012 , 18, 6290-301		12
90	Antiviral therapy delays esophageal variceal bleeding in hepatitis B virus-related cirrhosis. 2013 , 19, 6849-56		15
89	Review of the pharmacological management of hepatitis B viral infection before and after liver transplantation. 2013 , 19, 9189-97		24
88	Australian tertiary care outcomes of entecavir monotherapy in treatment naive patients with chronic hepatitis B. 2013 , 19, 721-6		3
87	Molecular diagnosis and treatment of drug-resistant hepatitis B virus. 2014 , 20, 5708-20		28
86	Then and now: the progress in hepatitis B treatment over the past 20 years. 2014 , 20, 401-13		40
85	Evolution of hepatitis B management in kidney transplantation. 2014 , 20, 468-74		13
84	Management of antiviral drug resistance in chronic hepatitis B. 2014 , 20, 11641-9		16

83	Practical approach in hepatitis B e antigen-negative individuals to identify treatment candidates. 2014 , 20, 12045-55		3
82	Hepatitis B and liver transplantation: molecular and clinical features that influence recurrence and outcome. 2014 , 20, 14142-55		15
81	Hepatitis B and human immunodeficiency virus co-infection. 2014 , 20, 17360-7		35
80	Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations. 2015 , 21, 10274-89		63
79	Management of entecavir-resistant chronic hepatitis B with adefovir-based combination therapies. 2015 , 21, 10874-82		9
78	Prophylactic managements of hepatitis B viral infection in liver transplantation. 2016 , 22, 165-75		11
77	Naturally occurring mutations in the reverse transcriptase region of hepatitis B virus polymerase from treatment-naïve Korean patients infected with genotype C2. 2017 , 23, 4222-4232		10
76	Naturally occurring hepatitis B virus reverse transcriptase mutations related to potential antiviral drug resistance and liver disease progression. 2018 , 24, 1708-1724		25
75	Investigation of immune escape-associated mutations of hepatitis B virus in patients harboring hepatitis B virus drug-resistance mutations. 2020 , 26, 5314-5327		2
74	Experience of anti-viral therapy in hepatitis B-associated membranous nephropathy, including Lamivudine-resistant strains. <i>Korean Journal of Internal Medicine</i> , 2012 , 27, 411-6	2.5	11
73	Long-term efficacy of tenofovir disoproxil fumarate therapy after multiple nucleos(t)ide analogue failure in chronic hepatitis B patients. <i>Korean Journal of Internal Medicine</i> , 2015 , 30, 32-41	2.5	15
72	Virologic response and safety of tenofovir versus entecavir in treatment-naïve chronic Hepatitis B patients. 2015 , 21, 146-51		8
71	Entecavir for treatment of chronic hepatitis B: A clinical update for the treatment of patients with decompensated cirrhosis. 2012 , 02, 53-61		1
70	Management of hepatitis B in developing countries. 2011 , 3, 292-9		27
69	Chronic hepatitis B: Advances in treatment. 2014 , 6, 284-92		24
68	Current and future directions for treating hepatitis B virus infection. 2015 , 7, 1541-52		21
67	Hepatitis B virus reactivation during immunosuppressive therapy: Appropriate risk stratification. 2015 , 7, 825-30		20
66	Metabonomic window into hepatitis B virus-related hepatic diseases. 2016 , 8, 1-8		3

65	Management of chronic hepatitis B with nucleoside or nucleotide analogues: a review of current guidelines. 2010 , 4, 15-24	13
64	Current Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B. 2011 , 5, 278-87	17
63	Continuous long-term entecavir therapy in naïve chronic hepatitis B patients showing partial virologic response. 2013 , 7, 712-8	13
62	Potential Efficacy of Pegylated Interferon- α and a Nucleos(t)ide Analogue as Combination Therapy for HBeAg-Positive Chronic Hepatitis B. 2016 , 10, 611-6	3
61	Predictive Value of Antiviral Effects in the Development of Hepatocellular Carcinoma in the General Korean Population with Chronic Hepatitis B. 2016 , 10, 962-968	7
60	Antiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma. 2012 , 1, 174-83	24
59	Efficacy of telbivudine with conditional tenofovir intensification in patients with chronic hepatitis B: results from the 2-year roadmap strategy. 2016 , 5, 212294	3
58	All-atom molecular dynamics study of hepatitis B virus containing pregenome RNA in solution. <i>Journal of Chemical Physics</i> , 2021 , 155, 145101	3.9 1
57	Chronic Hepatitis B. 2022 , 203-253	
56	[Predictors for virologic response in management of chronic hepatitis B]. <i>The Korean Journal of Hepatology</i> , 2010 , 16, 1-4	
55	Hepatology (I). 2010 , 500-546	
54	Hepatitis. 2010 , 608-616	
53	Mechanisms of Resistance to Antiviral Agents *. 2011 , 1710-1728	
52	Hepatitis B and D. 537-581	
51	Antiviral Therapy. 2012 , 903-921	
50	Antiviral Agents. 2012 , 1502-1518.e10	
49	Chronic hepatitis B. 603-609	
48	Clinical Efficacy of Entecavir and Factors Predicting Long-Term Treatment Response in Nucleoside-Naïve Patients with Chronic Hepatitis B. <i>Korean Journal of Medicine</i> , 2013 , 85, 157	0.5

47	Effect of Entecavir in Patients Who Lack Lamivudine Resistance after Lamivudine Treatment for Chronic Hepatitis B. <i>Korean Journal of Medicine</i> , 2013 , 84, 810	0.5	
46	HBV Therapy and the Problem of Drug Resistance. 2014 , 1-15		
45	Liver Disease among Renal Transplant Recipients. 2014 , 511-536		
44	Clinical Advances in Fibrosis Progression of Chronic Hepatitis B and C. <i>Journal of Clinical and Translational Hepatology</i> , 2014 , 2, 222-7	5.2	5
43	Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy. <i>Clinical and Molecular Hepatology</i> , 2015 , 21, 242-8	6.9	3
42	Effect of prophylactic versus preemptive lamivudine treatment and tenofovir on HBsAg+ kidney transplant recipients. <i>Experimental and Clinical Transplantation</i> , 2015 , 13, 35-40	0.8	2
41	Mechanisms of Resistance to Antiviral Agents. 1894-1912		1
40	Hepatitis B Recurrence: Major Milestones and Current Status. 2016 , 13-34		
39	Comparative evaluation of long-term monotherapies & combination therapies in patients with chronic hepatitis B: A pilot study. <i>Indian Journal of Medical Research</i> , 2016 , 144, 424-432	2.9	1
38	Nucleos(t)ide Analogue Based Therapy and Management of Patients. <i>Molecular and Translational Medicine</i> , 2016 , 339-359	0.4	
37	Chronic Hepatitis B, C, and D. 69-95		
36	Is it possible to predict the development of an entecavir resistance mutation in patients with chronic hepatitis B in clinical practice?. <i>Clinical and Molecular Hepatology</i> , 2017 , 23, 311-313	6.9	
35	Large-scale surveillance study of the safety and effectiveness of entecavir in Korean patients with chronic hepatitis B. <i>Korean Journal of Internal Medicine</i> , 2018 , 33, 91-101	2.5	1
34	Treatment of Hepatitis B. 2018 , 485-500.e5		
33	Efficacy of entecavir in treating hepatitis B virus-associated membranous nephropathy. <i>Revista Espanola De Enfermedades Digestivas</i> , 2020 , 112, 843-849	0.9	
32	Fungal metabolites: A potential source of antiviral compounds. 2020 , 157-173		
31	Hepatitis B and Hepatitis D Infections in the Transplant Setting. 2020 , 1-24		
30	Understanding the Genetics of Viral Drug Resistance by Integrating Clinical Data and Mining of the Scientific Literature.		

29	Alterations in Peripheral Lymphocyte Subsets in Early Stage of Novel Coronavirus Pneumonia. <i>SSRN Electronic Journal</i> ,	1	
28	Tenofovir plus entecavir combination therapy for chronic hepatitis B with nucleos(t)ide analogue failure. <i>The European Research Journal</i> ,	0	
27	Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response. <i>Clinical and Molecular Hepatology</i> , 2020 , 26, 352-363	6.9	1
26	Global prevalence and phylogeny of hepatitis B virus (HBV) drug and vaccine resistance mutations.		
25	Clinical Outcome Event Adjudication in a 10-Year Prospective Study of Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B. <i>Journal of Clinical and Translational Hepatology</i> , 2020 , 8, 377-384	5.2	0
24	The optimal threshold: Baseline serum hepatitis B virus DNA and alanine transaminase levels can predict the 2-Year on-treatment virological response to lamivudine. <i>Hepatitis Monthly</i> , 2011 , 11, 358-63	1.8	5
23	Molecular diagnosis of entecavir resistance. <i>Hepatitis Monthly</i> , 2010 , 10, 42-7	1.8	6
22	Initiation of liver transplantation in bangladesh: report on the first two successful cases. <i>Journal of Health, Population and Nutrition</i> , 2014 , 32, 696-700	2.5	3
21	Analysis of minimum target prices for production of entecavir to treat hepatitis B in high- and low-income countries. <i>Journal of Virus Eradication</i> , 2015 , 1, 103-10	2.8	14
20	A Review of Antiviral Use for the Treatment of Chronic Hepatitis B Virus Infection in Pregnant Women. <i>Gastroenterology and Hepatology</i> , 2017 , 13, 154-163	0.7	1
19	Viral Hepatitis B and C. Cure or Treatment?. <i>Thalassemia Reports</i> , 2014 , 4, 43-50	2	
18	Identification and Characterization of Besifovir-Resistant Hepatitis B Virus Isolated from a Chronic Hepatitis B Patient.. <i>Biomedicines</i> , 2022 , 10,	4.8	0
17	Therapeutic Advances in Viral Hepatitis 'A-E.. <i>Advances in Therapy</i> , 2022 , 39, 1524	4.1	
16	Renal safety of tenofovir disoproxil fumarate and entecavir in liver transplant patients: a nationwide Korean registry study.. <i>Hepatology International</i> , 2022 , 1	8.8	1
15	A small molecule targeting hepatitis B surface antigen inhibits clinically relevant drug-resistant hepatitis B virus.. <i>Journal of Antimicrobial Chemotherapy</i> , 2022 ,	5.1	0
14	Characterization of the tenofovir resistance-associated mutations in the hepatitis B virus isolates across genotypes A to D. <i>Antiviral Research</i> , 2022 , 203, 105348	10.8	1
13	Long-term follow-up of treatment-naïve HBeAg-negative patients with chronic hepatitis B. <i>Irish Journal of Medical Science</i> ,	1.9	0
12	Switching to tenofovir alafenamide for nucleos(t)ide analogue-experienced patients with chronic hepatitis B: Week 144 results from a real-world, multicentre cohort study. <i>Alimentary Pharmacology and Therapeutics</i> ,	6.1	0

11	Entry inhibition of hepatitis B virus using cyclosporin O derivatives with peptoid side chain incorporation. <i>Bioorganic and Medicinal Chemistry</i> , 2022 , 68, 116862	3.4	○
10	Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir Treatment for Chronic Hepatitis B Virus. <i>JAMA Network Open</i> , 2022 , 5, e2219407	10.4	○
9	Costs and health impact of delayed implementation of a national hepatitis B treatment program in China. <i>Journal of Global Health</i> , 12,	4.3	
8	Ocular side effects of drugs administered systemically for treatment of nonocular diseases. 2022 , 491-507		
7	Understanding the genetics of viral drug resistance by integrating clinical data and mining of the scientific literature. 2022 , 12,		○
6	Alanine aminotransferase levels as therapeutic targets after nucleotide/nucleoside analogue therapy in chronic hepatitis B patients.		○
5	One hundred and ninety-two weeks treatment of entecavir maleate for Chinese chronic hepatitis B predominantly genotyped B or C. 10, 10085-10096		○
4	Genomic Variability of Hepatitis B Virus Circulating in Brazilian Western Amazon. 2022 , 14, 2100		○
3	The Efficacy of Antiviral Treatment for Chronic Hepatitis B Patients with Normal ALT Levels: A Systematic Review and Meta-analysis. 2022 , 22,		○
2	Antiviral Agents. 2023 , 1583-1598.e6		○
1	Effect of nucleos(t)ide analogues on blood lipid profiles in patients with chronic hepatitis B: A cross-sectional survey. 2022 , 101, e31980		○